Societe Generale’s Kite Pharma, Inc. KITE Stock Holding History

Societe Generale’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$4.24M	Buy	+84,746	New	+$4.16M	0.03%	451

Other funds holding KITE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Societe Generale's KITE Position: Q2 2016 in Review

Societe Generale opened a new position in Kite Pharma, Inc. (KITE) in Q2 2016: 84,746 shares worth $4.24M. The stake represents 0.03% of the portfolio and ranks #451 among its holdings.

173 funds tracked by Wall St. Rank hold KITE as of Q2 2016.

Societe Generale held 84,746 shares of Kite Pharma, Inc. worth $4.24M as of Q2 2016.
Kite Pharma, Inc. was a new Societe Generale position in Q2 2016.
Kite Pharma, Inc. made up 0.03% of Societe Generale's portfolio in Q2 2016, its #451 holding.
173 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.